The decision was approved by the company’s Board of Directors at its meeting held on January 30, 2026.
The appointment was made based on the recommendation of the Nomination and Remuneration Committee and has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A(7) of Part A of Schedule III. Torrent Pharmaceuticals informed both the BSE and the National Stock Exchange of India about the change in senior management through an official regulatory filing.
According to the company, the appointment of Geena Malhotra as Chief Technology Officer has been approved in line with its internal policies. The disclosure has also been made in compliance with the SEBI Master Circular dated November 11, 2024, which outlines the reporting requirements for changes in senior management personnel.
Geena Malhotra brings nearly four decades of global experience in the pharmaceutical sector, spanning research and development, manufacturing, supply chain management, and sustainability. She is currently serving as the Managing Director of Signet Excipients, where she has been leading strategic growth initiatives, innovation partnerships, and digital transformation across pharmaceutical and biopharmaceutical segments since June 2024.
Earlier, she spent over 30 years at Cipla Ltd., holding several senior leadership roles. These included Global Chief Technology Officer and President from 2018 to 2024, President and Global Head of Manufacturing Operations, Supply Chain Management and Devices between 2013 and 2018, and Global Head – Integrated Product Development from 1994 to 2013. She also held leadership positions in research and development from 1986 to 1994. During her tenure, she played a key role in driving global product development, operational excellence, and innovation across formulations, inhalation devices, and drug delivery systems.
As per the disclosure, Geena Malhotra has been instrumental in securing around 50 international patents related to formulations, inhalation devices, and drug delivery technologies, supporting commercial products marketed in more than 80 countries. She has received several awards recognising her contributions to pharmaceutical innovation and leadership, including the Eminent Scientist Award in 2024, the FDD Leadership Award in 2017, the Thomson Reuters Innovation Award in 2012, and the Eminent Researcher Award from the Indian Pharmaceutical Association in 2007.
She holds an Executive MBA from Washington University in St. Louis – Olin Business School and a Bachelor of Pharmacy degree from SNDT University, Mumbai. The company has also clarified that there is no relationship between directors in relation to her appointment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.